Monitoring cabozantinib levels to manage side effects in kidney cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at whether closer monitoring of cabozantinib levels in the blood can help doctors manage side effects better. It's for people with advanced kidney cancer who are already planning to take cabozantinib.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic kidney cancer with clear cell type (the most common form).
- Your doctor plans to treat you with cabozantinib, either alone or with nivolumab.
- You are at least 18 years old.
- You are generally in good health (able to do light work or be fully active).
- If you or your partner could become pregnant, you must use effective birth control during treatment and for 4 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a “next-step” cabozantinib strategy for advanced kidney cancer (RCC) after your cancer previously responded to cabozantinib and then progressed. It aims to see if re-using cabozantinib in a planned sequence can control the cancer again with manageable side effects.
This trial tests two new drugs, belzutifan and zanzalintinib, for people with advanced kidney cancer that returned after or within 2 years of finishing an immunotherapy treatment after surgery. You cannot have received any other cancer treatments besides that immunotherapy.
This Phase 2 study tests how well nivolumab plus ipilimumab, along with cabozantinib, treats untreated or worsening kidney cancer that has spread to the brain. It may help shrink brain tumors and slow the disease when standard local brain treatments aren’t the right option.
This study tests the drug cabozantinib in people with kidney cancer who are also on dialysis. It aims to see if the drug is safe and works for this group.
This trial tests whether skipping a dose of cabozantinib instead of lowering the dose can help manage side effects while still controlling your kidney cancer. It is for people already taking cabozantinib who might need a break but want to stay on treatment.
This trial tests whether tracking your symptoms with a digital app can help manage side effects while you receive two medications (cabozantinib and nivolumab) for advanced clear-cell kidney cancer that hasn't been treated before.
Hear when a new Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.